2US0 Stock Chart & Stats
€4.73
€0.00(0.00%)
At close: 4:00 PM EDT
€4.73
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€4.54 - €4.73
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€20.31M
Enterprise Value-€7.31M
Total Cash (Recent Filing)€20.09M
Total Debt (Recent Filing)€4.29M
Price to Earnings (P/E)―
Beta2.58
Next Earnings
Oct 29, 2026EPS Estimate
-0.8Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-10.58
Shares Outstanding4,577,359
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.15
Price to Sales (P/S)0.00
P/FCF Ratio-0.81
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€17.84Price Target Upside277.18% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-5.66
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Relatively Low LeverageRelatively modest leverage reduces the company’s fixed financial burden compared with highly indebted peers and leaves less exposure to interest and refinancing pressure. Although the balance-sheet cushion is weakening, low debt may provide some flexibility while NextCure pursues development and strategic alternatives.
Narrowing LossesThe reduction in annual and trailing losses indicates some progress in controlling the cost base, even though profitability remains negative. If sustained, lower losses could extend financial runway and reduce the amount of external capital needed to support research programs and corporate operations.
Real-estate Cost ReductionExiting the Beltsville facility removes ongoing rent commitments and consolidates the company’s physical footprint. While the move involved a one-time $0.8 million fee, the elimination of recurring occupancy costs can support cash conservation over the next several quarters for a company with substantial operating burn.
Bears Say
No Commercial RevenueThe absence of revenue means NextCure has no established commercial product base to fund research and development internally. Its clinical-stage model therefore remains dependent on future collaboration economics, milestones, licensing proceeds, or financing rather than recurring product sales.
Persistent Cash Burn And Shrinking EquityContinued cash consumption shows that operations are not self-funding and may require additional external capital over time. The sharply reduced equity base further weakens the financial cushion, increasing the potential for dilution and limiting flexibility to sustain development programs through setbacks.
Reverse-split Legal UncertaintyUncertainty over the prior reverse split creates a structural execution risk around capitalization, Nasdaq compliance, and the proposed Avere transaction. An adverse court outcome could complicate share status and transaction timing, potentially disrupting strategic plans and stakeholder confidence.
NextCure News
2US0 FAQ
What was NextCure Inc’s price range in the past 12 months?
NextCure Inc lowest stock price was €4.54 and its highest was €4.73 in the past 12 months.
What is NextCure Inc’s market cap?
NextCure Inc’s market cap is €20.31M.
When is NextCure Inc’s upcoming earnings report date?
NextCure Inc’s upcoming earnings report date is Oct 29, 2026 which is in 3 days.
How were NextCure Inc’s earnings last quarter?
NextCure Inc released its earnings results on Aug 06, 2026. The company reported -€2.495 earnings per share for the quarter, missing the consensus estimate of -€1.738 by -€0.757.
Is NextCure Inc overvalued?
According to Wall Street analysts NextCure Inc’s price is currently Undervalued.
Does NextCure Inc pay dividends?
NextCure Inc does not currently pay dividends.
What is NextCure Inc’s EPS estimate?
NextCure Inc’s EPS estimate is -0.8.
How many shares outstanding does NextCure Inc have?
NextCure Inc has 4,577,359 shares outstanding.
What happened to NextCure Inc’s price movement after its last earnings report?
NextCure Inc reported an EPS of -€2.495 in its last earnings report, missing expectations of -€1.738. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of NextCure Inc?
Currently, no hedge funds are holding shares in DE:2US0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
NextCure Inc
NextCure, Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative immunotherapies. Its core mission is to combat cancer and various other immune-related conditions by reactivating normal immune system function. The company's leading investigational compound, NC318, is currently in Phase II clinical trials, focusing on the treatment of advanced or metastatic solid tumors. Additionally, NextCure is progressing NC410 through Phase I studies; this novel immunomedicine is engineered to counteract immune suppression mediated by Leukocyte-Associated Immunoglobulin-like Receptor 1 (LAIR-1). Another asset, NC762, is an immunotherapeutic designed to target the human B7 homolog 4 protein (B7-H4). Furthermore, NC525, a distinct LAIR-1 antibody, is undergoing preclinical assessment for its potential efficacy against acute myeloid leukemia, specifically targeting blast cells and leukemic stem cells. Beyond these specific pipeline candidates, NextCure's broader research and development efforts encompass the preclinical evaluation of other promising immunomodulatory antibodies and molecules. The company operates under a licensing agreement with Yale University. NextCure, Inc. was established in 2015 and maintains its corporate headquarters in Beltsville, Maryland.
2US0 Stock 12 Month Forecast
Average Price Target
€17.84
▲(277.18% Upside)
Technical Analysis
GT Biopharma
―
Marker Therapeutics
―
Celularity
―
Werewolf Therapeutics
―
Senti Biosciences
―